We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Eliane Schmidt

title picture web page

BioVersys announces first patient dosed in Phase 2 clinical trial with BV100

News / By

Basel, Switzerland. May 9, 2023, 9am CET BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today, that the first patient has been dosed in a multicenter Phase 2 clinical trial […]

BioVersys announces first patient dosed in Phase 2 clinical trial with BV100 Read More »

2023.01.31 tb ph2 dosing picture

BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098

News / By

Basel, Switzerland. January 31, 2023, 9am CET BioVersys AG announces first patient dosed in Phase 2a clinical trial with BVL-GSK099 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today, that

BioVersys announces first patient dosed in Phase 2a clinical trial with BVL-GSK098 Read More »

amr af pr picture

BioVersys extends its series C round to CHF 32.6 Million with investment from the AMR Action Fund

News / By

Basel, Switzerland. January 5, 2023, 1pm CET BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investment BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and

BioVersys extends its series C round to CHF 32.6 Million with investment from the AMR Action Fund Read More »

Kampf gegen Antibiotikaresistenzen: Die stille Pandemie

BioVersys in the News / By

Antibiotikaresistenzen bleiben weltweit eine wachsende Gefahr. Wie kann ihnen begegnet werden? Experten setzen auf bessere Information, gezielteren Einsatz und neue Wirkstoffe. Doch das Vergütungssystem erschwert deren Markteintritt. Ein Blick nach Großbritannien könnte die Lösung aufzeigen. Curious to read on?Below you will find the link to the full article published by Tagesspiegel Background Kampf gegen Antibiotikaresistenzen: Die

Kampf gegen Antibiotikaresistenzen: Die stille Pandemie Read More »

Bioversys successfully completes Phase I Flyer

BIOVERSYS SUCCESSFULLY COMPLETES PHASE I CLINICAL TRIALS OF BVL-GSK098

News / By

Basel, Switzerland. June 21, 2022, 9am CEST BioVersys AG announces successful completion of Phase I clinical trials with BVL-GSK098 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today the successful

BIOVERSYS SUCCESSFULLY COMPLETES PHASE I CLINICAL TRIALS OF BVL-GSK098 Read More »

Grafik schleichende Pandemie

Schleichende Pandemie

BioVersys in the News / By

Schon heute sterben mehr Menschen an bakteriellen Infektionskrankheiten als an HIV/Aids oderMalaria. Der Grund: Viele Antibiotika wirken nicht mehr. Wissenschaft ler und Pharmaherstellerfordern nun einen radikalen Politikwechsel: Zugang zu den Medikamenten, Forschungsanreize undVergütungssysteme müssten auf den Kopf gestellt werden. Curious to read on?Below you will find the link to the full article published by Tagesspiegel

Schleichende Pandemie Read More »

Advance pipeline of clinical assets Flyer Bioversys

BioVersys announces CHF 24.2 million financing to develop AMR clinical pipeline

News / By

Basel, Switzerland. June 8, 2022, 9am CEST BioVersys AG announces successful first closing of CHF 24.2 million Series C financing to develop clinical pipeline of novel AMR therapies BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation, announced

BioVersys announces CHF 24.2 million financing to develop AMR clinical pipeline Read More »

Mann im Anzug sitzt auf Business Sessel

ANTIBIOTICS ARE VICTIMS OF THEIR OWN SUCCESS!

BioVersys in the News / By

Despite the global increase in resistant pathogens, hardly any new antibiotics have come onto the market in recent decades. Marc Gitzinger, CEO of the Basel-based start-up BioVersys, calls for new reimbursement models for antibiotics. Curious to read on?Below you will find the link to the full article published by Handelskammer beider Basel. Antibiotika sind Opfer ihres

ANTIBIOTICS ARE VICTIMS OF THEIR OWN SUCCESS! Read More »

Mitarbeiter entnehmen Proben im Labor

BIOVERSYS SUCCESSFULLY COMPLETES THREE PHASE I CLINICAL TRIALS OF BV100

News / By

BioVersys AG announces successful completion of three Phase 1 of clinical trials with BV100 BioVersys AG, a privately-held clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today the successful completion of three Phase I

BIOVERSYS SUCCESSFULLY COMPLETES THREE PHASE I CLINICAL TRIALS OF BV100 Read More »

Scroll to Top